太平洋给予泓博医药买入评级：业绩实现强劲增长，Q2订单环比改善

Group 1 - The core viewpoint of the report is that Pacific Securities has given a "buy" rating for Hongbo Pharmaceutical (301230.SZ) based on strong performance indicators [1] - Market demand is recovering, leading to robust growth in performance [1] - Revenue from commercial production is rapidly increasing, enhancing profitability [1] - There is a quarter-on-quarter improvement in new orders signed in Q2, with a continuous increase in the number of clients [1] Group 2 - The report highlights potential risks including rising labor costs, talent attrition, environmental and safety production risks, product concentration in commercial production, and exchange rate fluctuations [1]